🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 20, 2026

The six filings for the S&P 500 Consumer Discretionary stream reveal a bifurcated sector. Ross Stores delivered a standout quarter with 13% sales growth and a 610 bps operating margin expansion, though this was heavily inflated by one-time tariff refunds, and forward guidance points to a sharp normalization. In contrast, insider activity at eBay shows a routine, low-materiality sale by a senior executive, while Yum Brands insider activity reflects standard equity compensation exercises with no bearish signal. Ford Motor Credit's delisting is a non-event, purely administrative. Carvana's two filings detail a large $1.55B asset-backed securitization, signaling continued access to capital markets for growth, though with no new operational data. The overarching theme is one of strong current performance (Ross) contrasted with cautious forward guidance, while capital markets activity (Carvana) remains robust. No portfolio-level trends are discernible due to the small, disparate sample, but the Ross Stores filing is the most actionable for its materiality and the implied earnings cliff from the tariff refunds.

4 high priority 2 medium 6 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — August 20, 2026

The six filings from the S&P 500 Healthcare sector reveal a sector bifurcated between significant litigation risk and routine insider activity. The most critical development is Abbott Laboratories' $670 million settlement of preterm infant formula litigation, which, while removing a major overhang, leaves ~1,700 lawsuits pending, signaling ongoing legal risk. Insider trading patterns are mixed: a large, non-10b5-1 sale by a Stryker director for $44.2 million and a planned sale by a Cigna executive under a 10b5-1 plan suggest potential bearish conviction at those firms, while a tax-withholding sale at Regeneron is neutral. Thermo Fisher's HR officer executed a large option exercise and simultaneous sale, a routine but notable cash-out. No period-over-period financial trends or forward-looking guidance were available in these filings, limiting the ability to assess growth or margin trends. The overall theme is one of event-driven risk (litigation) and insider sentiment divergence, with no clear sector-wide bullish catalyst from this data set.

5 high priority 1 medium 6 total filings
· daily

US Earnings Financial Results SEC Filings — August 20, 2026

The 18 filings for the period ending August 20, 2026, reveal a bifurcated market. Mature, cash-flow-positive companies like Applied Materials and Nordson are delivering strong earnings growth, while a significant number of pre-revenue or distressed SPACs and micro-caps continue to burn cash with widening losses, creating a stark 'haves vs. have-nots' landscape. Key period-over-period trends include acute margin compression and revenue decline at Flux Power and Wolfspeed, partially offset by turnarounds at Advance Auto Parts and solid growth at ScanSource. Several companies (Flux Power, Farmhouse, BioKey, GBT Technologies, Arterior Solutions) face severe balance sheet strain with stockholders' deficits and going-concern risks. Capital allocation is mixed, with Applied Materials slowing buybacks while increasing capex, and Prospect Capital seeing a dramatic pullback in new investments. The most critical developments are the multiple liquidity crises among smaller filers and the post-bankruptcy restructuring at Wolfspeed, which presents both risk and a potential turnaround opportunity. Sector patterns suggest that industrial and financial firms are generally outperforming, while consumer staples (Flowers Foods) and legacy auto parts (Advance Auto Parts still facing sales declines) are under pressure.

18 high priority 18 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 20, 2026

The single filing in this stream pertains to Bio-Techne Corporation, which is being acquired by Merck KGaA for $73.00 per share in cash, a transaction valued at approximately $1.5 billion. The filing is a proxy statement for a special meeting on September 23, 2026, to approve the merger. The board unanimously recommends a vote 'FOR' the proposal, and the filing also includes advisory votes on executive compensation. The sentiment is positive, and the materiality is rated 10/10, indicating a highly significant event for shareholders. No period-over-period trends, insider trading activity, or other enriched data points are available beyond the merger details. The key development is the pending acquisition, which offers a clear premium to shareholders, but also raises questions about the company's future as an independent entity.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 20, 2026

The IPO pipeline is active with four S-1 filings on August 20, 2026, but the overall picture is bifurcated between traditional IPOs and distressed resale registrations. The two traditional IPOs—ARC Group Acquisition II (a SPAC) and Orion180 Insurance Group—are structurally neutral, offering unit structures and dual-class control respectively, with no pricing details yet. In stark contrast, the two resale filings (NEXGEL and HCW Biologics) reveal significant financial distress, with NEXGEL facing a severe authorized share shortage and going concern doubts, and HCW Biologics relying on a PIPE transaction for a clinical-stage pipeline. The most critical development is NEXGEL's existential capital structure crisis, which overshadows the pipeline with high materiality (9/10). Period-over-period comparisons are limited as these are initial filings, but the forward-looking data and capital allocation signals paint a clear picture: the pipeline is a mix of clean slate IPOs and distressed secondary offerings, demanding a highly selective approach from investors.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — August 20, 2026

The August 20, 2026, batch of 35 filings reveals a period of significant leadership transition across US equities, with a notable concentration of CFO changes (Coty, Boston Beer, Ingredion, LSI Industries, Skyward Specialty, Popular) and strategic board refreshments. A key portfolio-level trend is the 'orderly succession' pattern, where outgoing CFOs are retained as advisors (Merit Medical, LSI Industries, Skyward Specialty) to ensure continuity, signaling a focus on stability. The most critical development is Sysco's creation of an AI Transformation & Technology Committee alongside a $100M AI-driven cost-savings program, which, combined with reiterated FY2027 guidance of 6-7% revenue growth, presents a strong bullish catalyst. Conversely, a high-risk flag is the complete change in control at Rocky Mountains Group, where a single shareholder acquired 83.2% voting control, triggering a full executive replacement, creating extreme governance uncertainty. Overall, the digest points to a market where companies are proactively managing talent risk and investing in technology, but isolated events of concentrated ownership change warrant close monitoring.

35 high priority 35 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 20, 2026

The 'USA Board Room Changes' stream over August 20, 2026, reveals a significant wave of leadership transitions, with a clear emphasis on CFO and C-suite succession planning across diverse sectors. Key trends include a high volume of orderly, non-contentious executive departures (e.g., Boston Beer, LSI Industries, Skyward Specialty) and the appointment of external executives with deep digital transformation and technology expertise (e.g., Victoria's Secret, Sysco, Rigetti Computing). Notable period-over-period comparisons are sparse in these event-driven filings, but forward-looking statements from Sysco (FY2027 guidance of 6-7% revenue growth with a $100M AI cost-savings plan) and Rigetti's restructuring to scale quantum systems provide actionable investment themes. A critical

35 high priority 35 total filings
· daily

USA Insider Trading Pulse — August 20, 2026

The August 20, 2026 insider trading pulse reveals a market dominated by broad-based insider selling, particularly concentrated in the healthcare and technology sectors. The most significant cluster is at **Cardinal Health**, where six senior executives, including the CEO and CFO, collectively sold over $19 million in stock, signaling deep-seated concern about the company's near-term outlook. In contrast, a few high-conviction insider purchases stand out, notably a $36.4 million buy by a 10% owner at **Republic Services** and a $2.7 million purchase by a director at **AParadise Acquisition Corp.**, suggesting strong bullish conviction in these names. The data also shows a pattern of routine option exercises and tax-withholding sales, which are less directional, but the sheer volume of open-market selling by C-suite executives across multiple sectors warrants a cautious stance. The overall sentiment is bearish, with 28 negative signals versus only 5 positive ones, driven by a lack of forward-looking guidance upgrades and a prevalence of 10b5-1 plan sales that may mask underlying bearish sentiment.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 20, 2026

The August 20, 2026 M&A digest is dominated by two mega-deals closing: Santander's acquisition of Webster Financial and Charter Communications' transformative acquisitions of Liberty Broadband and Cox Communications. These transactions, valued at billions, reshape the banking and telecom landscapes, respectively, but carry significant integration and balance sheet risks. The SPAC sector shows a stark divergence: while RF Acquisition Corp II and Bleichroeder Acquisition Corp II advance toward business combinations, Rising Dragon Acquisition Corp faces a Nasdaq delisting threat, highlighting the ongoing shakeout in the blank-check space. A new SPAC IPO (NorthStrive) signals continued capital formation for manufacturing deals. The overall sentiment is mixed, with bullish execution on major deals tempered by bearish signals in SPAC compliance and post-deal financial health.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 20, 2026

Overnight SEC filings reveal a mixed but actionable landscape. Insider activity is notable: significant buying at Li Bang International and Chicago Atlantic BDC, while heavy selling at Cerebras Systems, Equity Residential, and Netlist signals caution. A major development is JBS's non-binding proposal to acquire the remaining ~18% of Pilgrim's Pride, implying a value of ~$28.49 per share, which could drive PPC shares. Knorex reported a sharp revenue decline of 44.2% YoY and a widening net loss, flagging operational distress. Office Properties Income Trust's emergence from bankruptcy with Redwood Capital's 18% stake and board rights presents a potential restructuring opportunity. AST SpaceMobile's broad insider awards suggest confidence in future growth. Overall, the data highlights selective opportunities in special situations and insider conviction, while warning of deteriorating fundamentals in some names.

50 high priority 50 total filings
· daily

Biotech Small-Cap Approvals — August 19, 2026

This digest covers three FDA approvals from August 14-17, 2026, all classified as 'Other' (FALLBACK type), with zero NMEs, biosimilars, or label expansions. The approvals include two label expansions—one for SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTD and one for BAXTER HLTHCARE CORP—and one biosimilar approval for PROPRANOLOL HYDROCHLORIDE by CREEKWOOD PHARMS. No dominant therapeutic area theme emerges due to undisclosed drug names and indications. The highest-conviction signal is the two bullish signals for the label expansions, though materiality and strength are moderate (5/10 each) and commercial details are entirely NOT_DISCLOSED, limiting actionable insight. Key risk is the lack of transparency on drug identity, indication size, and pricing, making investment thesis development highly speculative.

3 total filings
· daily

New Drug Approvals (Original) — August 19, 2026

The August 19, 2026, approval period delivered three non-NME, non-biosimilar, non-label-expansion approvals, all classified as 'Other' (likely manufacturing/formulation updates or minor variations). The mix is notably devoid of high-value NMEs or biosimilars, resulting in a muted investment signal overall. Two bullish signals were generated from label expansions by SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTD and BAXTER HLTHCARE CORP, though the specific drugs and indications remain undisclosed, limiting conviction. A neutral signal from CREEKWOOD PHARMS' approval of PROPRANOLOL HYDROCHLORIDE (a generic beta-blocker) suggests no immediate competitive disruption. The key risk is the lack of transparency around the 'Unknown' drugs, which obscures therapeutic area clustering and commercial implications. Investors should monitor for detailed FDA labeling documents to assess true opportunity size.

3 total filings
· daily

DHS Homeland Security Contracts — August 19, 2026

The digest covers a single, high-materiality $270.4 million civilian contract awarded by DHS/ICE to GEO Group subsidiary B.I. Incorporated for the Intensive Supervision Appearance Program (ISAP IV). This is a purely civilian award with no defense component, signaling sustained demand for detention compliance and supervision services under full and open competition. The highest-conviction signal is bullish for GEO Group, given the material revenue contribution of approximately $231.8 million annualized. Key risks include the fixed-price contract structure, which carries performance risk, and the absence of options beyond September 2025, creating near-term re-compete uncertainty.

1 total filings
· daily

New Federal Contractors — August 19, 2026

The two contracts analyzed total $444.6 million in obligations, both from civilian agencies (0% defense-related), signaling stable but non-defense-oriented federal spending. The dominant theme is ICE's continued demand for detention compliance services, led by GEO Group subsidiary B.I. Incorporated's $270.4 million delivery order for the ISAP IV program—a high-conviction bullish signal for GEO Group. The second contract, a $174.1 million sole-source award to Universal Service Administrative Company (USAC) by the FCC, is neutral for public investors as USAC is a nonprofit. Key risk: GEO Group's fixed-price contract carries medium performance risk, and the ISAP IV contract ends September 2025 without options, creating a re-compete cliff.

2 total filings
· daily

Significant Contract Modifications ($10M+) — August 19, 2026

The two contracts analyzed, totaling $444.6 million, are entirely civilian in nature, with zero defense-related awards. The dominant theme is stable, non-competitive government spending on administrative and supervision services, led by a $270.4 million ICE delivery order to GEO Group subsidiary B.I. Incorporated for the ISAP IV program. This award is the highest-conviction signal, indicating sustained demand for detention compliance services. A key risk is the fixed-price structure of the B.I. Incorporated contract, which carries performance risk, and the fact that the second-largest award ($174.1 million) went to a non-public entity (USAC), offering no direct public market exposure.

2 total filings
· daily

Contract Deobligations Alert — August 19, 2026

This digest covers $444.6 million in total obligations across two civilian agency contracts, with zero defense-related awards. The dominant signal is a $270.4 million firm-fixed-price delivery order from ICE to GEO Group subsidiary B.I. Incorporated for the Intensive Supervision Appearance Program (ISAP IV), representing a high-conviction bullish signal for GEO Group given its materiality (8/10) and full-competition win. The second award, a $174.1 million sole-source contract to nonprofit Universal Service Administrative Company (USAC) by the FCC, is neutral for public markets due to USAC's non-traded status. Key risk: GEO Group’s fixed-price structure carries medium performance risk, and the contract ends September 2025 with no options, creating re-compete uncertainty.

2 total filings
· daily

Contract Option Exercises — August 19, 2026

The two contracts analyzed total $444.6 million in obligations, with zero defense-related awards, underscoring a purely civilian procurement landscape dominated by the Department of Homeland Security (DHS). The highest-conviction signal is a $270.4 million firm-fixed-price delivery order awarded to GEO Group subsidiary B.I. Incorporated for ICE’s Intensive Supervision Appearance Program (ISAP IV), representing a bullish 7/10 signal with high materiality. This contract signals sustained government demand for detention compliance services despite fixed-price performance risk. A separate $174.1 million sole-source award to nonprofit Universal Service Administrative Company (USAC) by the FCC is neutral and offers limited public market relevance. Key risks include potential ICE budget reallocations and the fixed-price structure’s margin pressure on GEO Group.

2 total filings
· daily

Federal Professional Services Contracts — August 19, 2026

A single, non-defense civilian contract worth $174.1 million to the Universal Service Administrative Company (USAC) from the Federal Communications Commission (FCC) dominated the period. The award is a fully funded, multi-year sole-source for administrative management services, providing stable revenue to a non-public entity. This digest offers no actionable public equity signals, as the recipient is a nonprofit and the work is low-margin administrative support. The key watch item is the contract's impending December 2025 expiration and potential re-compete, which could introduce competitive pressure on advisory firms supporting telecom infrastructure policy.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — August 19, 2026

The two contracts tracked in this digest total $444.6 million in obligations, with zero defense-related awards, underscoring a purely civilian procurement focus this period. The dominant signal is a $270.4 million firm-fixed-price delivery order from ICE to GEO Group subsidiary B.I. Incorporated for the Intensive Supervision Appearance Program (ISAP IV), representing a high-conviction, near-term revenue catalyst for GEO Group. A secondary $174.1 million sole-source award to the nonprofit Universal Service Administrative Company (USAC) by the FCC provides stable but non-actionable revenue for a non-public entity. The key risk is the fixed-price structure on the B.I. Incorporated contract, which carries medium performance risk, and the lack of defense exposure limits sector-wide tailwinds.

2 total filings